Targeting interleukin-17 receptor B enhances gemcitabine sensitivity through downregulation of mucins in pancreatic cancer.Published in:Scientific Reports, 2020, v. 10, n. 1, p. 1, doi. 10.1038/s41598-020-73659-zBy:Tsai, Lung-Hung;Hsu, Kai-Wen;Chiang, Cheng-Ming;Yang, Hsiu-Ju;Liu, Yu-Huei;Yang, Shun-Fa;Peng, Pei-Hua;Cheng, Wei-Chung;Wu, Heng-HsiungPublication type:Article